Report top-line results for the Phase 3 INVIGORATE study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Reproxalap allergic conjunctivitis Phase 3 INVIGORATE study top-line results H1 2021”
What we found
Evidence strength A What the grades mean
The company announced in April 2021 that the Phase 3 INVIGORATE clinical trial had achieved its primary and secondary endpoints, meeting the commitment to report results within the first half of 2021.
-
A Aldeyra Therapeutics, Inc. 10-K filed 2022-03-17
“In April 2021, we announced that the randomized, double-masked, vehicle-controlled allergen chamber Phase 3 INVIGORATE clinical trial of 0.25% reproxalap in patients with AC 16 (Figure 7) achieved the primary endpoint” ✓ confirmed on the page
Market reaction: the shares moved +12.3% against the S&P 500 over the three sessions around the disclosure (16 Mar 2022 to 21 Mar 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 INVIGORATE study top-line results
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALDX-021255 · Corrections policy